611 related articles for article (PubMed ID: 19220880)
21. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):58-64. PubMed ID: 17973208
[TBL] [Abstract][Full Text] [Related]
22. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis.
Cigrovski Berkovic M; Petrovski G; Grulovic N
Acta Diabetol; 2016 Oct; 53(5):709-15. PubMed ID: 27098531
[TBL] [Abstract][Full Text] [Related]
24. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
[TBL] [Abstract][Full Text] [Related]
25. Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes.
Oya J; Nakagami T; Hasegawa Y; Katamine A; Kondo Y; Babazono T
J Diabetes Investig; 2021 Nov; 12(11):1983-1991. PubMed ID: 33938149
[TBL] [Abstract][Full Text] [Related]
26. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies.
Davies M; Sinnassamy P; Storms F; Gomis R;
Diabetes Res Clin Pract; 2008 Feb; 79(2):368-75. PubMed ID: 17980928
[TBL] [Abstract][Full Text] [Related]
27. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
28. Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life.
Pujante Alarcón P; Rodríguez Escobedo R; García Urruzola F; Ares J; Manjón L; Sanchez Ragnarson C; Cacho L; Delgado E; Menéndez Torre EL
Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):210-216. PubMed ID: 30559088
[TBL] [Abstract][Full Text] [Related]
29. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
[TBL] [Abstract][Full Text] [Related]
30. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
Davies M; Evans R; Storms F; Gomis R; Khunti K
Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis.
Nakanishi S; Iwamoto M; Kamei S; Hirukawa H; Shimoda M; Tatsumi F; Kohara K; Obata A; Kimura T; Kinoshita T; Irie S; Sanada J; Fushimi Y; Nishioka M; Mizoguchi A; Kameyama M; Mune T; Kaku K; Kaneto H
Intern Med; 2018; 57(10):1381-1389. PubMed ID: 29760318
[TBL] [Abstract][Full Text] [Related]
32. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
[TBL] [Abstract][Full Text] [Related]
33. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
Dornhorst A; Lüddeke HJ; Honka M; Ackermann RW; Meriläinen M; Gallwitz B; Sreenan S;
Curr Med Res Opin; 2008 Feb; 24(2):369-76. PubMed ID: 18096110
[TBL] [Abstract][Full Text] [Related]
35. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
36. Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts.
Giugliano D; Tracz M; Shah S; Calle-Pascual A; Mistodie C; Duarte R; Sari R; Woo V; Jiletcovici AO; Deinhard J; Wille SA; Kiljanski J
Diabetes Care; 2014 Feb; 37(2):372-80. PubMed ID: 24170763
[TBL] [Abstract][Full Text] [Related]
37. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
38. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
39. [Long-term evaluation of patients with type 1 diabetes mellitus treated with insulin glargine].
Haladová I; Lacigová S; Cechurová D; Jankovec Z; Krcma M; Rusavý Z
Vnitr Lek; 2009 Nov; 55(11):1016-21. PubMed ID: 20017431
[TBL] [Abstract][Full Text] [Related]
40. Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.
Philis-Tsimikas A; Zhang Q; Walker C
Am J Ther; 2006; 13(6):466-72. PubMed ID: 17122525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
